Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.
Goldvaser H, Yerushalmi R, Mutai R, Kuchuk I, Toker M, Paluch-Shimon S, Drumea K, Evron E, Sonnenblick A, Gal-Yam E, Sela GB, Shai A, Merose R, Bareket-Samish A, Soussan-Gutman L, Stemmer SM. Goldvaser H, et al. Among authors: shai a. Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07549-7. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39560822
Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.
Brenner B, Shulman K, Hubert A, Man S, Geva R, Ben-Aharon I, Fennig S, Mishaeli M, Yarom N, Bar-Sela G, Brenner R, Shai A, Baehner FL, Russell C, Soussan-Gutman L, Voet H, Bareket-Samish A, Liebermann N. Brenner B, et al. Among authors: shai a. ESMO Open. 2024 Aug;9(8):103648. doi: 10.1016/j.esmoop.2024.103648. Epub 2024 Aug 12. ESMO Open. 2024. PMID: 39137478 Free PMC article.
HER2-Low Breast Cancer: Current Landscape and Future Prospects.
Shirman Y, Lubovsky S, Shai A. Shirman Y, et al. Among authors: shai a. Breast Cancer (Dove Med Press). 2023 Aug 14;15:605-616. doi: 10.2147/BCTT.S366122. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37600670 Free PMC article. Review.
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS; COURSE study investigators. Singh D, et al. Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6. Lancet Respir Med. 2025. PMID: 39653044 Clinical Trial.
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Lucas CG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, Ravindranathan A, Shai A, Oberheim Bush NA, Taylor JW, de Groot J, Villanueva-Meyer JE, Pekmezci M, Perry A, Bollen AW, Theodosopoulos PV, Aghi MK, Chang EF, Hervey-Jumper SL, Raleigh DR, Molinaro AM, Costello JF, Diaz AA, Clarke JL, Butowski NA, Phillips JJ, Chang SM, Berger MS, Solomon DA. Lucas CG, et al. Among authors: shai a. Neuro Oncol. 2025 Jan 12;27(1):89-105. doi: 10.1093/neuonc/noae214. Neuro Oncol. 2025. PMID: 39560080 Free PMC article.
155 results